Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials

被引：36

作者：

Genne, D ^{[1
]}

Kaiser, L ^{[1
]}

Kinge, TN ^{[1
]}

Lew, D ^{[1
]}

机构：

[1] Univ Hosp Geneva, Div Infect Dis, Geneva, Switzerland

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2003年 / 9卷 / 09期

关键词：

community-acquired pneumonia; treatment failure; antibiotic;

D O I：

10.1046/j.1469-0691.2003.00679.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

In order to determine the causes of treatment failure in community-acquired pneumonia (CAP) clinical trials, a MEDLINE search for all CAP studies published between 1990 and 1997 was performed. Prospective, randomized studies comparing the efficacy of two or more antibiotics in CAP were selected. Treatment failure was defined as persistent fever, deterioration of patient's condition, or a change in the prescribed antibiotic regimen. In 16% of the cases included in the clinical trials, the treatment of CAP is unsuccessful. A significant number of identified failure cases were owing to antibiotic side-effects. Resistant pathogens are an unusual cause of failure whatever the antibiotic used.

引用

收藏

页码：949 / 954

页数：6

相关论文

共 32 条

[1] A COMPARATIVE SAFETY AND EFFICACY STUDY OF CLARITHROMYCIN AND ERYTHROMYCIN STEARATE IN COMMUNITY-ACQUIRED PNEUMONIA [J].

ANDERSON, G ;

ESMONDE, TS ;

COLES, S ;

MACKLIN, J ;

CARNEGIE, C .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :117-124

[2] EFFICACY AND SAFETY OF AZITHROMYCIN VERSUS BENZYLPENICILLIN OR ERYTHROMYCIN IN COMMUNITY-ACQUIRED PNEUMONIA [J].

BOHTE, R ;

VANTWOUT, JW ;

LOBATTO, S ;

ALBLAS, ABV ;

BOEKHOUT, M ;

NAUTA, EH ;

HERMANS, J ;

VANDENBROEK, PJ .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1995, 14 (03) :182-187

[3] EFFICACY AND SAFETY OF TEMAFLOXACIN VERSUS THOSE OF AMOXICILLIN IN HOSPITALIZED ADULTS WITH COMMUNITY-ACQUIRED PNEUMONIA [J].

CARBON, C ;

LEOPHONTE, P ;

PETITPRETZ, P ;

CHAUVIN, JP ;

HAZEBROUCQ, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (04) :833-839

[4] TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA - A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY COMPARING CLARITHROMYCIN WITH ERYTHROMYCIN [J].

CHIEN, SM ;

PICHOTTA, P ;

SIEPMAN, N ;

CHAN, CK .

CHEST, 1993, 103 (03) :697-701

[5] COMPARISON OF CEFOTAXIME WITH CEFTRIAXONE GIVEN INTRAMUSCULARLY 12-HOURLY FOR COMMUNITY-ACQUIRED PNEUMONIA [J].

DANSEY, RD ;

JACKA, PJ ;

STRACHAN, SA ;

HAY, M .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1992, 15 (01) :81-84

[6]

DAVEY P, 1994, BRIT J GEN PRACT, V44, P509

[7]

DAVEY PG, 1995, AM J MED S6B, V99, P20

[8] Prognosis and outcomes of patients with community-acquired pneumonia - A meta-analysis [J].

Fine, MJ ;

Smith, MA ;

Carson, CA ;

Mutha, SS ;

Sankey, SS ;

Weissfeld, LA ;

Kapoor, WN .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (02) :134-141

[9] PENICILLIN-G OFLOXACIN VERSUS ERYTHROMYCIN AMOXICILLIN-CLAVULANATE IN THE TREATMENT OF SEVERE COMMUNITY-ACQUIRED PNEUMONIA [J].

GAILLAT, J ;

BRU, JP ;

SEDALLIAN, A .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1994, 13 (08) :639-644

[10] Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia [J].

Genné, D ;

Siegrist, HH ;

Humair, L ;

Janin-Jaquat, B ;

de Torrenté, A .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1997, 16 (11) :783-788

← 1 2 3 4 →